Abbvie Inc.

Bayer Intellectual Property Gmbh

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Bayer Pharma Aktiengesellschaft

Nicole Teusch

Alexandros Vakalopoulos

Katja Zimmermann

Martin Michels

Markus Follmann

Helmut Mack

Anil Vasudevan

Adrian Hobson

Bernhard K Mueller

Mario Lobell

Martin Schmidt

Karen Engel

Tariq Ghayur

Achim Moeller

Mario Mezler

Reinhold Mueller

Eve H Barlow

Steven Lewis Swann, Jr

Axel Meyer

Thomas Dale Penning

Wilfried Hornberger

Stevan Wakefield Djuric

Sean Colm Turner

Julie M Miyashiro

Alan Frank Gasiecki

Keith W Woods

Jyoti R Patel

Daryl Richard Sauer

Qi Shuai

Irini Akritopoulou-Zanze

Ryan G Keddy

Kathy A Sarris

Douglas M Kalvin

Biqin C Li

Dawn M George

Lu Wang

Brian D Wakefield

Melissa J Michmerhuizen

Dominique Bonafoux

Vijaya J Gracias

Andrew J Long

Michael F Jarvis

Eric F Johnson

Peter J Kovar

Hans Briem

Shendong Yuan

Ulrich Ebert

Donald Bierer

Achim Möller

Ralf Loebbert

Alfred Hahn

Margaretha Bakker

Margaretha H M Bakker

Nigel S Moore

Bernhard K Muller

N St John Moore

Steve Swann, Jr

Maria Kissel

Bernhard K MÜLLER

Ryan Keddy

Adrian Donald Hobson

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

The present invention relates to novel fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.

AGER-peptides and use thereof

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

This invention relates to novel 4-(indazol-5-yl)-4,7-dihydroisoxazolo[5,4-b]pyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

The present invention relates to novel, fluoro-substituted 2-aryl-3,5-dicyano-4-(1H-indazol-5-yl)-6-methyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly Cancer and other proliferative disorders.

Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof

The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). Rand Rare, independently of each other, hydrogen, hydroxy, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy or C-C-haloalkoxy; R, R, Rand Rare, independently of each other, hydrogen, hydroxy, halogen, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy, C-C-haloalkoxy, amino, C-C-alkylamino or di-(C-C-alkyl)-amino; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, aryl or aryl-C-C-alkyl; Ris a group of the formula &#x2014;X&#x2014;W, where X is a single bond, C-C-alkylene or C-C-alkylene-O&#x2014;, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; Ris a group of the formula &#x2014;Y&#x2014;Z, where Z is hydrogen, halogen, OR, NRR, S(O)&#x2014;R, phenyl which may carry 1, 2, 3 or 4 substituents Ror a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched CC-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond. 

4-(4-pyridinyl)-benzamides and their use as rock activity modulators

This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof

This invention relates to novel annellated 4-(indazolyl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof

This invention relates to novel 4-(furo[3,2-c]pyridin-2-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof

This invention relates to novel 4-(indazolyl)-1,4-dihydropyridine of the following formula (I) derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders. 

Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)

Growing community of inventors

Wülfrath, Germany

Nicole Teusch